FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval
June 10, 2024 at 15:56 PM EDT
If approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the market after Leqembi from Biogen and Eisai.
